

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00647 A1

(51) International Patent Classification⁷: **C07H 21/04**,
21/02, C12N 15/85, 15/86, A61K 35/00, 48/00, C12Q 1/68

(74) Agents: **LICATA, Jane, Massey et al.**; Law Offices of
Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053
(US).

(21) International Application Number: **PCT/US00/16489**

(22) International Filing Date: **15 June 2000 (15.06.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
09/344,579 **25 June 1999 (25.06.1999) US**

(71) Applicant (for all designated States except US): **ISIS
PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday
Avenue, Carlsbad, CA 92008 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAKER, Brenda**,
F. [US/US]; 2147 Avenida Toronja, Carlsbad, CA 92009
(US). **COWSERT, Lex, M.** [US/US]; 3008 Newshire
Street, Carlsbad, CA 92008 (US).

(54) Title: **ANTISENSE MODULATION OF ETS-2 EXPRESSION**

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ets-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ets-2. Methods of using these compounds for modulation of Ets-2 expression and for treatment of diseases associated with expression of Ets-2 are provided.

WO 01/00647 A1